用着司美格鲁肽，突然发现怀孕了？别慌，先把这几步做对

Core Viewpoint - The article discusses the implications of using Semaglutide, a GLP-1 receptor agonist, during pregnancy, highlighting the risks of unintended pregnancy and the necessary precautions for women using this medication [5][6]. Group 1: Semaglutide Overview - Semaglutide is a GLP-1 receptor agonist that improves blood sugar levels, reduces appetite, and delays gastric emptying, making it useful for treating type 2 diabetes and weight management [6]. - There is insufficient data on the safety of Semaglutide during pregnancy, leading to conservative clinical recommendations against its use during this period [6]. Group 2: Risks of Unintended Pregnancy - The likelihood of unintended pregnancy while using Semaglutide is increased due to several factors, including irregular ovulation in women with obesity or PCOS, gastrointestinal side effects affecting oral contraceptive absorption, and a lack of long-term contraceptive planning [8]. - Women using Semaglutide should prioritize contraception as a necessary safety measure if they do not plan to conceive [8]. Group 3: Recommendations for Pregnancy Planning - It is advised to stop using Semaglutide at least two months before attempting to conceive to minimize the risk of early embryo exposure to the drug [9]. - This recommendation aims to distance the fertilization and early embryonic development stages from the potential drug exposure window [9]. Group 4: Actions After Unintended Pregnancy - Upon discovering an unintended pregnancy, the first step is to stop Semaglutide and seek professional evaluation, noting the last injection date, dosage, and purpose of the medication [10]. - It is crucial not to discontinue all diabetes medications without professional guidance, especially for those with pre-existing conditions like diabetes or abnormal glucose tolerance [10]. Group 5: Monitoring and Management During Pregnancy - Regular prenatal checks should focus on key screening points, including early pregnancy assessments for chromosomal abnormalities and mid-pregnancy structural ultrasounds [11]. - Continuous monitoring of maternal metabolic status and fetal growth is essential, as underlying conditions like obesity and insulin resistance pose more significant risks than the medication itself [11]. - Post-discontinuation of Semaglutide, it is important to manage weight and metabolic health proactively to avoid complications during pregnancy [11].